Bayer CEO Restructures Firm 'Like a Speedboat'
Bayer CEO Bill Anderson is restructuring the 100,000-person company by flattening hierarchies and empowering smaller, more agile teams. The goal, according to Sequoia Capital's podcast, is to turn the 168-year-old "tanker" into a "speedboat" capable of faster execution. This approach of creating small, outcome-oriented squads is cited as a relevant model for designing modern platform engineering organizations.
- The new operating model, "Dynamic Shared Ownership" (DSO), replaces traditional annual planning with rapid 90-day cycles, intending to push 95% of decision-making to self-managed, cross-functional teams. - This restructuring is a response to significant financial pressure, including a 28% stock value drop in 2023 and ongoing U.S. litigation costs stemming from the company's acquisition of Monsanto. - CEO Bill Anderson was previously the CEO of Roche's pharmaceutical division and CEO of Genentech, where he led a transformation that resulted in significant revenue growth and was involved in launching 25 new medicines. - The plan includes cutting approximately 12,000 jobs and reducing management positions by about 50% to achieve €2 billion ($2.3 billion) in annual savings by 2026. - Early results of the DSO model include some customer-focused teams doubling their revenues in a single 90-day cycle and a key product reaching the market a year ahead of schedule. - The company's executive board was reduced from 14 members to eight in March 2024 to streamline high-level decision-making. - Despite the internal overhaul, Bayer's pharmaceutical division's sales grew 4.1% year-on-year in the first quarter of 2025, driven by strong performance from newer drugs like the cancer therapy Nubeqa and kidney disease treatment Kerendia.
